Latest news with #CSLBehring
Reuters
10-02-2025
- Business
- Reuters
Australia's CSL reports half-year profit jump on strong demand for immunoglobulin products
Feb 11 (Reuters) - Australia's biotech giant CSL Ltd ( opens new tab reported a 5% rise in its first-half profit on Tuesday, boosted by growth in its core immunoglobulin business across geographies, while low U.S. immunisation rates weighed on its influenza products unit. Strong underlying demand for CSL's immunoglobulin (Ig) products for the treatment of patients with chronic immune system disorders drove up sales. Total revenue from the company's largest division, Behring, for the six months ended December 31 rose 10% to $5.74 billion. CSL Behring includes the Ig products segment, whose sales grew 15% year over year. The Melbourne-based firm has been in the process of improving CSL Behring's gross profit margins by introducing the efficient "RIKA Plasma Donation System" technology across its plasma collection business. The company expects the RIKA roll-out to be completed across CSL Plasma by the end of the financial year, it said. Meanwhile, revenue for CSL Seqirus, the company's influenza-related products division, fell 9%. "CSL Seqirus was negatively impacted by significantly low influenza immunisation rates, particularly in the United States," CEO Paul McKenzie said. The firm said that its underlying net profit after tax attributable for the half year was $2.11 billion, on a constant currency basis, compared with $2.06 billion reported a year ago. On a reported currency basis, its profit was $2.07 billion, missing a Visible Alpha consensus estimate of $2.16 billion. CSL reassured investors that it continues to expect annualised double-digit earnings growth over the medium term. It declared an interim dividend of $1.30 per share, higher than $1.19 per share declared a year ago.
Globe and Mail
28-01-2025
- Business
- Globe and Mail
Hemophilia A FDA Approvals, Clinical Trials, Pipeline Insights, Drugs and Companies
DelveInsight's, 'Hemophilia A Pipeline Insight' report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Hemophilia A pipeline landscape. It covers the Hemophilia A pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia A therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hemophilia A Treatment Landscape. Click here to read more @ Hemophilia A Pipeline Outlook Key Takeaways from the Hemophilia A Pipeline Report In January 2025:- CSL Behring:- A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Previously Treated Patients (PTPs) With Hemophilia A. For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than [<] 1%). In January 2025:- Octapharma:-Female patients with mild to moderate haemophilia A will often need FVIII concentrates to provide haemostatic cover during major surgery. This prospective, open-label, non-controlled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq in women/girls over 12 with haemophilia A undergoing major surgery requiring FVIII treatment. In January 2025:- Bayer:- A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A. By replacing the defective gene with a healthy copy the human body may produce clotting factor on its own. Hemophilia A is a bleeding disorder in which the human body does not have enough clotting factor VIII, a protein that controls bleeding. Researcher want to find the optimal dose of BAY 2599023 (DTX201) so that the body may produce enough clotting factor on its own. DelveInsight's Hemophilia A pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Hemophilia A treatment. The leading Hemophilia A Companies such as Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others. Promising Hemophilia A Pipeline Therapies such as Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others. Discover groundbreaking developments in Hemophilia A therapies! Gain in-depth knowledge of key Hemophilia A clinical trials, emerging drugs, and market opportunities @ Hemophilia A Clinical Trials Assessment Hemophilia A Emerging Drugs Profile AGN-193408: Allergan Allergan is conducting a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-group (Cohort 2) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension. It is an implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. OCTA101: Octapharma Octapharma is evaluating OCTA101 (a human-cl rhFVIII and recombinant human von Willebrand Factor fragment dimer) under a Phase 1/2 study, which will be a dose escalation study in adults in 5 cohorts, with the main purpose to assess the safety of subcutaneous injection of OCTA101 (in previously treated adult patients with severe hemophilia A. The study also aims to assess the pharmacokinetics (PK) characteristics, dose proportionality, and subcutaneous bioavailability of OCTA101 compared with intravenous administration of Nuwiq (Human-cl rh FVIII), in order to define the prophylactic treatment (dose and injection interval) that would result in protective trough levels of FVIII:C for future Phase 3 studies. By Data Monitoring Committee recommendation, patients enrolled in cohorts 1, 2 and 3 will proceed to 3-month prophylactic treatment to receive daily dosing of OCTA101 for 3 months. Valoctocogene roxaparvovec: BioMarin Pharmaceuticals Valoctocogene roxaparvovec, is an investigational gene therapy in clinical trials for the treatment of Hemophilia A and has not been determined to be safe or effective. Valoctocogene roxaparvovec is administered as a single infusion. The ongoing clinical trials will determine if the new gene will enable the body to produce factor VIII. Following infusion, clinical trial subjects are being evaluated to determine the safety profile, changes in Factor VIII activity levels, changes in factor replacement usage, changes in reported bleeds requiring factor replacement, and quality of life measures, among other endpoints. Hemophilia A Companies Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others. Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Molecule Type Hemophilia A Products have been categorized under various Molecule types such as Small molecules Gene Therapies Bispecific antibodies Recombinant proteins Fusion Proteins Coagulants Blood coagulation factor replacements Transform your understanding of the Hemophilia A Pipeline! See the latest progress in drug development and clinical research @ Hemophilia A Market Drivers and Barriers, and Future Perspectives Scope of the Hemophilia A Pipeline Report Coverage- Global Hemophilia A Companies- Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others. Hemophilia A Pipeline Therapies- Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others. Hemophilia A Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hemophilia A Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Genetic Disorders Research–Access the Full Hemophilia A Pipeline Analysis Today! @ Hemophilia A Drugs and Companies Table of Content 1. Introduction 2. Executive Summary 3. Hemophilia A: Overview 4. Pipeline Therapeutics 5. Therapeutic Assessment 6. Hemophilia A - DelveInsight's Analytical Perspective 7. In-depth Commercial Assessment 8. Hemophilia A Collaboration Deals 9. Late Stage Products (Pre-registration) 10. Valoctocogene roxaparvovec: BioMarin Pharmaceutical 11. Late Stage Products (Phase III) 12. Giroctocogene fitelparvovec: Pfizer/ Sangamo Therapeutics 13. Mid Stage Products (Phase II) 14. NNC0365-3769 A (Mim8): Novo Nordisk A/S 15. Early Stage Products (Phase I/II) 16. BAX 888: Baxalta / Shire 17. BAY2599023: Bayer / Ultragenix pharmaceutical 18. Early Stage Products (Phase I) 19. Gene therapy: Expression Therapeutics, LLC 20. Drug profiles in the detailed report….. 21. Hemophilia A- Market Drivers and Barriers 22. Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 9650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
